Business
Onco3R Therapeutics Appoints Lawrence Blatt as Chair of the Board for Onco3R Therapeutics
Leuven, Belgium. January 8, 2026. Onco3R Therapeutics, a clinical-stage immunology and oncology biotech company dedicated to transforming patients’ lives with best-in-class medicines, today announced the appointment of Lawrence M. Blatt, PhD, MBA as Chair of its Board of Directors. Dr. Blatt brings substantial expertise in strategic leadership, drug development and operations together with extensive experience, to guide and support Onco3R’s portfolio development and its next stage of growth. He
About this update from Aligos Therapeutics, Inc.
[{"type":"image","alt":"Onco3R Therapeutics BV","displaySize":"","headline":null,"caption":"Onco3R Therapeutics BV","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":91,"url":"https://media.zenfs.com/en/globenewswire.com/ba00095092a2d7b18afbe3f5953357f1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/G7.QKNzkR4ztpCZpGZuIog--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ba00095092a2d7b18afbe3f5953357f1","width":300,"height":91}},"lazy":false},{"type":"text","content":"Leuven, Belgium. January 8, 2026. Onco3R Therapeutics, a clinical-stage immunology and oncology biotech company dedicated to transforming patients’ lives with best-in-class medicines, today announced the appointment of Lawrence M. Blatt, PhD, MBA as Chair of its Board of Directors.","length":282,"tagName":"p"},{"type":"text","content":"Dr. Blatt brings substantial expertise in strategic leadership, drug development and operations together with extensive experience, to guide and support Onco3R’s portfolio development and its next stage of growth. He has been serving as Chief Executive Officer and a member of the board of directors at Aligos Therapeutics, Inc. since February 2018. Prior to co-founding Aligos, Dr. Blatt served as the Global Head of Infectious Diseases and Vaccines at Janssen Pharmaceutical Companies of Johnson & Johnson, a pharmaceutical company. Dr. Blatt co-founded Alios BioPharma and served as its Chief Executive Officer, President and Director from 2009 until its acquisition by Janssen Pharmaceutical Companies of Johnson & Johnson for $1.75 billion in 2014. Prior to Alios, he served as Chief Scientific Officer at lnterMune. Dr. Blatt previously served on the board of directors of ReViral Ltd. and Alveo Technologies, which he co-founded, and Meissa Vaccines.","length":965,"tagName":"p"},{"type":"text","content":"“We are delighted to welcome Larry to the board of Onco3R as Chairman” said Pierre Raboisson, PhD, CEO and Founder of Onco3R Therapeutics. “He brings a perfect mixture of strategic acumen, deep scientific insight and commercial expertise that will help us to achieve our ambitious goals.”","length":288,"tagName":"p"},{"type":"text","content":"Dr. Blatt added “I have worked with Pierre and many of the Onco3R team previously and have first-hand experience of their world class...